Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management

  • ID: 2105527
  • January 2012
  • Region: Global
  • 51 Pages
  • CBR Pharma Insights
1 of 3

Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. It's potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy.

Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases protect sales after generics enter. However in order to achieve this companies must focus increasingly on demonstrating provable benefits, ideally in head to head trials against the original product. This has become necessary as increasingly cost conscious healthcare providers promote the use of generic therapies unless clear advantages are demonstrated.

Biologics increasing dominance of the pharmaceutical market opens new opportunities in reformulation and will drive the sectors future success. Opportunities to deliver less frequent dosing or more convenient and lower cost formulations will continue to drive the development of new technologies.

The report, “Reformulation READ MORE >

Note: Product cover images may vary from those shown
2 of 3

Chapter 1: Introduction to reformulation strategies
- What is reformulation
- What drives pharma companies to reformulate
- The importance of reformulation to big pharma
- What makes a successful reformulation strategy
- Optimizing reformulation strategies
- Drug formulations: the main options

Chapter 2: Analysis of the key drivers of reformulation in the pharmaceutical market
- Drug delivery companies and reformulation specialists as a driving force
- Reformulation a key option in lifecycle management
- The rise of biologic therapies and "biobetters“
- New technologies:
- orally disintegrating tablets
- anti-tamper technologies
- nanotechnology

Chapter 3: Focus on controlled release reformulation strategies
- Oral controlled release:
- the options
- technologies used
- case study analysis
- technology provider profiles
Injectable controlled release:
- technology provider profiles
- case study analysis


Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown





Our Clients

  • UBS AG
  • Mannkind Corporation
  • KPMG
  • BearingPoint
  • Svenska Cellulosa Aktiebolaget SCA
  • AlixPartners, LLP